# AVITA MEDICAL LTD ACN 058 466 523

## **NOTICE OF GENERAL MEETING**

TIME: 11.00AM EST

**DATE**: Monday 24 August 2015

**PLACE**: Level 12, 15 William Street

Melbourne VIC 3000

This Notice of Meeting should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting.

Should you wish to discuss the matters in this Notice of Meeting please do not hesitate to contact the Company Secretary on +61 8 9474 7738.

CONTENTS	
Business of the Meeting (setting out the proposed Resolutions)	4
Explanatory Statement (explaining the proposed Resolutions)	6
Glossary	12
Proxy Form	

#### IMPORTANT INFORMATION

## Time and place of Meeting

Notice is given that the Meeting will be held at 11am EST on 24 August 2015 at:

Level 12, 15 William Street Melbourne VIC 3000

## Your vote is important

The business of the Meeting affects your shareholding and your vote is important.

#### Voting eligibility

The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001 (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at 4pm EST on Saturday 22 August 2015.

#### Voting in person

To vote in person, attend the Meeting at the time, date and place set out above.

#### Voting by proxy

To vote by proxy, please complete and sign the enclosed Proxy Form and return by the time and in accordance with the instructions set out on the Proxy Form.

In accordance with section 249L of the Corporations Act, Shareholders are advised that:

- each Shareholder has a right to appoint a proxy;
- the proxy need not be a Shareholder of the Company; and
- a Shareholder who is entitled to cast 2 or more votes may appoint 2 proxies and may specify the proportion or number of votes each proxy is appointed to exercise. If the member appoints 2 proxies and the appointment does not specify the proportion or number of the member's votes, then in accordance with section 249X(3) of the Corporations Act, each proxy may exercise one-half of the votes.

Shareholders and their proxies should be aware that changes to the Corporations Act made in 2011 mean that:

- if proxy holders vote, they must cast all directed proxies as directed; and
- any directed proxies which are not voted will automatically default to the Chair, who
  must vote the proxies as directed.

Further details on these changes are set out below.

## Proxy vote if appointment specifies way to vote

Section 250BB(1) of the Corporations Act provides that an appointment of a proxy may specify the way the proxy is to vote on a particular resolution and, **if it does**:

- the proxy need not vote on a show of hands, but if the proxy does so, the proxy must vote that way (ie as directed); and
- if the proxy has 2 or more appointments that specify different ways to vote on the resolution, the proxy must not vote on a show of hands; and
- if the proxy is the chair of the meeting at which the resolution is voted on, the proxy must vote on a poll, and must vote that way (ie as directed); and
- if the proxy is not the chair, the proxy need not vote on the poll, but if the proxy does so, the proxy must vote that way (ie as directed).

### Transfer of non-chair proxy to chair in certain circumstances

Section 250BC of the Corporations Act provides that, if:

- an appointment of a proxy specifies the way the proxy is to vote on a particular resolution at a meeting of the Company's members; and
- the appointed proxy is not the chair of the meeting; and
- at the meeting, a poll is duly demanded on the resolution; and
- either of the following applies:
  - the proxy is not recorded as attending the meeting; or
  - > the proxy does not vote on the resolution,

the chair of the meeting is taken, before voting on the resolution closes, to have been appointed as the proxy for the purposes of voting on the resolution at the meeting.

#### BUSINESS OF THE MEETING

#### **AGENDA**

#### 1. RESOLUTION 1 – RATIFICATION OF PRIOR ISSUE OF SHARES – ASX LISTING RULE 7.1

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 48,796,261 Shares on the terms and conditions set out in the Explanatory Statement."

**Voting Exclusion**: The Company will disregard any votes cast on this Resolution by a person who participated in the issue and any associates of those persons. However, the Company need not disregard a vote if it is cast by a person as a proxy for a person who is entitled to vote, in accordance with the directions on the Proxy Form, or, it is cast by the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the Proxy Form to vote as the proxy decides.

#### 2. RESOLUTION 2 - RATIFICATION OF PRIOR ISSUE OF SHARES – ASX LISTING RULE 7.1A

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution:

"That, for the purpose of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 32,530,840 Shares on the terms and conditions set out in the Explanatory Statement."

**Voting Exclusion:** The Company will disregard any votes cast on this Resolution by a person who participated in the issue and any of their associates. However, the Company need not disregard a vote if it is cast by a person as a proxy for a person who is entitled to vote in accordance with the directions on the Proxy Form or it is cast by the person chairing the Meeting as proxy for a person who is entitled to vote, in accordance with a direction on the Proxy Form to vote as the proxy decides.

## 3. RESOLUTION 3 –APPROVAL TO ISSUE SHARES UNDER PLACEMENT

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purposes of ASX Listing Rule 7.1 and for all other purposes, approval is given for the Company to issue up to that number of Shares, when multiplied by the issue price, will raise up to \$20,000,000 on the terms and conditions set out in the Explanatory Statement."

**Voting Exclusion**: The Company will disregard any votes cast on this Resolution by any person who may participate in the proposed issue and a person who might obtain a benefit, except a benefit solely in the capacity of a holder of ordinary securities, if the Resolution is passed and any associates of those persons. However, the Company need not disregard a vote if it is cast by a person as a proxy for a person who is entitled to vote, in accordance with the directions on the Proxy Form, or, it is cast by the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the Proxy Form to vote as the proxy decides.

#### 4. RESOLUTION 4 – ADOPTION OF EMPLOYEE SHARE PLAN INCENTIVE PLAN

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purpose of ASX Listing Rule 7.2 (Exception 9(b)) and for all other purposes, the Plan be approved for the issue of securities under that Plan, on the terms and conditions set out in the Explanatory Statement."

**Voting Exclusion**: The Company will disregard any votes cast on this Resolution by any Director, other than any Directors who are ineligible to participate in any employee incentive scheme in relation to the Company, and any associates of those Directors. However, the Company need not disregard a vote if it is cast by a person as a proxy for a person who is entitled to vote, in accordance with the directions on the Proxy Form, or, it is cast by the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the Proxy Form to vote as the proxy decides.

#### **Voting Prohibition Statement**

A person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if:

- (a) the proxy is either:
  - (i) a member of Key Management Personnel; or
  - (ii) a Closely Related Party of such a member; and
- (b) the appointment does not specify the way the proxy is to vote on this Resolution.

However, the above prohibition does not apply if:

- (a) the proxy is the Chair; and
- (b) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of Key Management Personnel.

Dated: 21 July 2015

By order of the Board

GABRIEL CHIAPPINI
Company Secretary

## **EXPLANATORY STATEMENT**

This Explanatory Statement has been prepared to provide information which the Directors believe to be material to Shareholders in deciding whether or not to pass the Resolutions.

#### 1. RESOLUTION 1 – RATIFICATION OF PRIOR ISSUE OF SHARES - ASX LISTING RULE 7.1A

#### 1.1 General

As announced on 12 March 2015, the Company completed an institutional placement of 81,327,101 Shares at a price of \$0.062 per Share to sophisticated and professional investors, raising approximately \$5.04 million (**Placement**).

Of these Placement shares, 48,796,261 were issued without Shareholder approval under ASX Listing Rule 7.1. This Resolution seeks Shareholder ratification pursuant to ASX Listing Rule 7.4 for the issue of those Shares (**7.1 Ratification**). Shareholder ratification of the remaining 32,530,840 Shares is the subject of Resolution 2.

ASX Listing Rule 7.1 provides that a company must not, subject to specified exceptions, issue or agree to issue more equity securities during any 12 month period than that amount which represents 15% of the number of fully paid ordinary securities on issue at the commencement of that 12 month period.

ASX Listing Rule 7.4 sets out an exception to ASX Listing Rule 7.1. It provides that where a company in general meeting ratifies the previous issue of securities made pursuant to ASX Listing Rule 7.1 (and provided that the previous issue did not breach ASX Listing Rule 7.1) those securities will be deemed to have been made with shareholder approval for the purpose of ASX Listing Rule 7.1.

By ratifying this issue, the Company will retain the flexibility to issue equity securities in the future up to the 15% annual placement capacity set out in ASX Listing Rule 7.1 without the requirement to obtain prior Shareholder approval.

#### 1.2 Technical information required by ASX Listing Rule 7.4

Pursuant to and in accordance with ASX Listing Rule 7.5, the following information is provided in relation to the 7.1 Ratification:

- (a) 48,796,261 Shares were issued;
- (b) the issue price was \$0.062 per Share;
- (c) the Shares issued were all fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares;
- (d) the Shares were issued to sophisticated and professional investors who are not related parties of the Company;
- (e) the funds raised from this issue were used for:
  - (i) the recruitment of commercial personnel;
  - (ii) sales and marketing initiatives;
  - (iii) clinical research funding to initiate new randomised controlled trials;

- (iv) new clinical collaborations and feasibility studies; and
- (v) general working capital expenditure.

#### 1.3 Board recommendation

The Directors unanimously recommend Shareholders vote in favour of this Resolution.

#### 2. RESOLUTION 2 - RATIFICATION OF PRIOR ISSUE – SHARES – ASX LISTING RULE 7.1A

#### 2.1 General

As part of the Placement, 32,530,840 Shares were issued under ASX Listing Rule 7.1A pursuant to the Company's additional placement capacity under Listing Rule 7.1A.

At the time of issue, ASX Listing Rule 7.1A was not breached.

This Resolution seeks Shareholder ratification pursuant to ASX Listing Rule 7.4 of the prior Placement of 32,530,840 Shares issued under ASX Listing Rule 7.1A (7.1A Ratification).

## 2.2 ASX Listing Rule 7.1A

ASX Listing Rule 7.1A enables an Eligible Entity to seek shareholder approval at its annual general meeting to issue Equity Securities in addition to those under the Eligible Entity's 15% annual placement capacity.

An Eligible Entity is one that, as at the date of the relevant annual general meeting:

- 2.2.1 is not included in the S&P/ASX 300 Index; and
- 2.2.2 has a maximum market capitalisation (excluding restricted securities and securities quoted on a deferred settlement basis) of \$300,000,000,

#### (Eligible Entity).

The Company currently has on issue 424,950,013 Shares and the last recorded closing price of the Shares on 15 July 2015 was \$0.088 cents. The Company is an Eligible Entity as it is not included in the S&P/ASX 300 Index and has a current market capitalisation of less than \$300,000,000.

Any Equity Securities issued must be in the same class as an existing class of quoted Equity Securities. The Company currently has one class of quoted Equity Securities on issue, being ordinary Shares (ASX Code: AVH).

The exact number of Equity Securities that the Company may issue under an approval under Listing Rule 7.1A will be calculated according to the following formula:

Where:

- A is the number of Shares on issue 12 months before the date of issue or agreement to issue:
  - (i) plus the number of Shares issued in the previous 12 months under an exception in ASX Listing Rule 7.2;

- (ii) plus the number of partly paid shares that became fully paid in the previous 12 months;
- (iii) plus the number of Shares issued in the previous 12 months with approval of holders of Shares under Listing Rules 7.1 and 7.4; and
- (iv) less the number of Shares cancelled in the previous 12 months.
- **D** is 10%.
- is the number of Equity Securities issued or agreed to be issued under ASX Listing Rule 7.1A.2 in the 12 months before the date of issue or agreement to issue that are not issued with the approval of holders of Ordinary Securities under ASX Listing Rule 7.1 or 7.4.

ASX Listing Rule 7.4 provides that where a company in general meeting ratifies the previous issue of securities made pursuant to ASX Listing Rule 7.1A those securities will from that date be included in variable "A" in the formula in ASX Listing Rules 7.1 and 7.1A.2 for the purpose of calculating the annual placement capacity of the Company under both ASX Listing Rules 7.1 and 7.1A.

By ratifying the issue subject to this Resolution, the Company will retain the flexibility to issue equity securities in the future up to the 10% Placement Capacity set out in ASX Listing Rule 7.1A without the requirement to obtain prior Shareholder approval.

#### 2.3 Technical information required by ASX Listing Rule 7.4

Pursuant to and in accordance with ASX Listing Rule 7.5, the following information is provided in relation to the 7.1A Ratification:

- (a) 32.530,840 Shares were issued:
- (b) the issue price was \$0.062 per Share;
- (c) the Shares issued were all fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares;
- (d) the Shares were issued to sophisticated and professional investors who are not related parties of the Company;
- (e) the funds raised from this issue were used for:
  - (i) the recruitment of commercial personnel;
  - (ii) sales and marketing initiatives;
  - (iii) clinical research funding to initiate new randomised controlled trials;
  - (iv) new clinical collaborations and feasibility studies; and
  - (v) general working capital expenditure.

#### 2.4 Board recommendation

The Directors unanimously recommend Shareholders vote in favour of this Resolution.

#### 3. RESOLUTION 3 – APPROVAL TO ISSUE SHARES UNDER PLACEMENT

## 3.1 Background

Life Sciences is a capital intensive industry. In order to continue being successful, it is important that Avita is able to attract the required capital and human resources to adequately support its growth initiatives and for this reason it is looking to raise up to \$20 million pursuant to this Resolution.

Specific initiatives include both accelerating the commercial adoption of the Company's products as well as undertaking the clinical studies require to obtain regulatory approval in the United States and support attractive reimbursement in all global markets.

In an effort to increase liquidity in the stock and attract US institutional investors the company is planning an uplisting of the current US OTCQX exchange onto NASDAQ or New York Stock Exchange (NYSE MKT) (**US Uplisting**). This initiative aims to open up access to a large number of sophisticated global investors that are limited to only acquiring stock on the larger US exchanges.

#### 3.2 General

This Resolution seeks Shareholder approval for the issue of up to that number of Shares, when multiplied by the issue price, will raise up to \$20,000,000 (**Placement**).

A summary of ASX Listing Rule 7.1 is contained in Section 1.1.

The effect of this Resolution will be to allow the Company to issue the Shares pursuant to the Placement during the period of 3 months after the Meeting (or a longer period, if allowed by ASX), without using the Company's 15% annual placement capacity.

#### 3.3 Technical information required by ASX Listing Rule 7.1

Pursuant to and in accordance with ASX Listing Rule 7.3, the following information is provided in relation to the Placement:

- (a) the maximum number of Shares to be issued is such number when multiplied by the issue price enables the Company to raise up to \$20,000,000;
- (b) the Shares will be issued no later than 3 months after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the ASX Listing Rules) and it is intended that issue of the Shares will occur on the same date:
- (c) the issue price will be not less than 80% of the volume weighted average price for Shares calculated over the 5 days on which sales in the Shares are recorded before the day on which the issue is made or, if there is a prospectus, over the last 5 days on which sales in the securities were recorded before the date the prospectus is signed;
- (d) the Shares will be issued to various parties to which the Company is entitled to issue Shares without the need to issue a disclosure document under Section 708 of the Corporations Act. None of these subscribers are related parties of the Company;
- (e) the Shares issued will be fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares; and

(f) the Company intends to use the funds raised from the Placement as set out in the following table:

	Maximum		
Commercial Initiatives	\$6,466,667		
Reimbursement programmes	\$200,000		
Clinical programmes	\$5,066,667		
Regulatory filings	\$266,667		
Research and Development	\$1,333,333		
U.S. Securities Exchange up-listing	\$1,333,333		
Costs of the offer	\$2,000,000		
Working Capital	\$3,333,333		
TOTAL	\$20,000,000		

#### 3.4 Dilution

The volume weighted average price for Shares on the 5 days on which sales in Shares were recorded before 16 July 2015 was \$0.085. The lowest issue price (ie maximum discount) of not less than 80% of this volume weighted average price would be \$0.068 per Share.

Accordingly, set out below is a worked example of the number of Shares that may be issued under this Resolution based on an assumed issue price of \$0.068, \$0.078 and \$0.088.

Assumed issue price	Maximum number of Shares which the Company could issue (rounded up to the nearest whole number) pursuant to this Resolution	Current Shares on issue as at the date of this Notice	Increase in the number of Shares on issue assuming the Company issued the maximum amount pursuant to this Resolution	Dilution effect on existing Shareholders
0.068	294,117,647	424,950,013	719,067,760	41%
0.078	256,410,256	424,950,013	681,360,369 38	
0.088	227,272,727	424,950,013	652,222,840	35%

Assuming no Options are exercised or other Shares issued and the maximum number of Shares as set out in the worked example above are issued, the number of Shares on issue would increase from 424,950,013 (being the number of Shares on issue as at the date of this Notice) to 719,067,760 and the shareholding of existing Shareholders would be diluted by approximately 41%.

The Company notes that the above workings are an example only and the actual issue price may differ. This will result in the maximum number of Shares to be issued and the dilution percentage to also differ.

#### 3.5 Board recommendation

The Directors unanimously recommend Shareholders vote in favour of this Resolution.

#### 4. RESOLUTION 4 – ADOPTION OF EMPLOYEE SHARE PLAN

#### 4.1 General

This Resolution seeks the approval of Shareholders for the Company to issue securities under the Plan (an employee incentive plan) in accordance with ASX Listing Rule 7.2 (Exception 9(b)).

The Plan has been designed to assist with the attraction, motivation and retention of Eligible Employees, align the interests of those Eligible Employees and Shareholders by matching rewards with the long term performance of the Company and, accordingly, continue to drive the Company's improved performance. The Plan has not been previously approved by Shareholders.

A summary of ASX Listing Rule 7.1 is contained in Section 1.1.

ASX Listing Rule 7.2 (Exception 9(b)) sets out an exception to ASX Listing Rule 7.1 which provides that issues under an employee incentive scheme are exempt for a period of 3 years from the date on which shareholders approve the issue of securities under the scheme as an exception to ASX Listing Rule 7.1.

If this Resolution is passed, the Company will be able to grant Shares under the Plan to Eligible Employees over a period of 3 years from the date of approval without impacting on the Company's ability to issue up to 15% of its total ordinary securities without Shareholder approval in any 12 month period.

A material feature of the Plan is the issue of Shares pursuant to the Plan may be undertaken by way of provision of a non-recourse, interest free loan to be used for the purposes of subscribing for the Shares based on a price that will be not less than the volume weighted average price at which Shares were traded on the ASX over the 10 trading days up to and including the date of acceptance of the offer.

Any future issues of Shares under the Plan to a related party or a person whose relation with the company or the related party is, in ASX's opinion, such that approval should be obtained will require additional Shareholder approval under ASX Listing Rule 10.14 at the relevant time.

#### 4.2 Technical information required by ASX Listing Rule 7.2 (Exception 9(b))

The following information is provided pursuant to and in accordance with ASX Listing Rule 7.2 (Exception 9(b)):

- (a) A summary of the key terms and conditions of the Plan is set out in Schedule A. In addition, a copy of the Plan is available for review by Shareholders at the registered office of the Company until the date of the Meeting. A copy of the Plan will also be sent to Shareholders upon request.
- (b) Shareholders have not previously approved the adoption of the Plan, therefore, no Shares have been granted under the Plan since it was last approved.
- (c) A voting exclusion statement is set out on page 5 of the Notice of Meeting accompanying this Explanatory Statement.

## 4.3 Board recommendation

The Directors unanimously recommend Shareholders vote in favour of this Resolution.

#### **GLOSSARY**

\$ means Australian dollars.

**ASIC** means the Australian Securities & Investments Commission.

**ASX** means ASX Limited (ACN 008 624 691) or the financial market operated by ASX Limited, as the context requires.

ASX Listing Rules means the Listing Rules of ASX.

**Board** means the current board of directors of the Company.

**Business Day** means Monday to Friday inclusive, except New Year's Day, Good Friday, Easter Monday, Christmas Day, Boxing Day, and any other day that ASX declares is not a business day.

Chair means the chair of the Meeting.

Company means Avita Medical Ltd (ACN 058 466 523).

**Constitution** means the Company's constitution.

Corporations Act means the Corporations Act 2001 (Cth).

**Directors** means the current directors of the Company.

**Equity Securities** means as defined in the ASX Listing Rules.

**EST** means Eastern Standard Time as observed in Melbourne, Victoria.

**Explanatory Statement** means the explanatory statement accompanying the Notice.

**General Meeting** or **Meeting** means the meeting convened by the Notice.

**Notice** or **Notice** of **Meeting** means this notice of meeting including the Explanatory Statement and the Proxy Form.

**Plan** means the Avita Medical Ltd Employee Share Plan.

**Proxy Form** means the proxy form accompanying the Notice.

**Resolutions** means the resolutions set out in the Notice, or any one of them, as the context requires.

**Share** means a fully paid ordinary share in the capital of the Company.

**Shareholder** means a registered holder of a Share.

## SCHEDULE A - SUMMARY OF EMPLOYEE SHARE PLAN

The following is a summary of the key terms and conditions of the Employee Share Plan to be adopted by Shareholders under Resolution 4:

- (a) **Eligible Employees:** Parties eligible to participate in the Employee Share Plan include Directors, and full-time or part-time employee, casual employee or consultant of the Company, or any of its subsidiaries and any other related bodies corporate of the Company or any other person that ASIC declares is eligible to receive a grant of Shares under the Plan and who are declared by the Board as eligible to receive grants of Shares under the Employee Share Plan (**Eligible Employees**).
- (b) **Administration of Plan**: The Board is responsible for the operation of the Plan and has a broad discretion to determine which Participants will be offered Shares under the Plan.
- (c) **Offer:** The Board may issue an offer to an Employee to participate in the Plan. The offer:
  - (i) will invite application for the number of Shares specified in the offer;
  - (ii) will specify the issue price for the Shares or the manner in which the Issue Price is to be calculated;
  - (iii) may invite applications for a loan up to the amount payable in respect of the Shares accepted by the Employee in accordance with the offer;
  - (iv) will specify any vesting conditions applying to the Shares;
  - (v) will specify the date of allocation or intended date of allocation; and
  - (vi) specify any other terms and conditions attaching to the Shares.
- (d) **Consideration**: Shares granted under the Employee Share Plan will be issued for such consideration as determined by the Board in their absolute discretion as at the time of the proposed issue of the Shares which equates to an arm's length market price, taking into account among other factors (i) recent trading volumes, (ii) the price at which Shares traded over the relevant period and (iii) other factors determined by the Board to be relevant
- (e) **Vesting Conditions:** Shares may be subject to a vesting condition which must be satisfied before the Shares are registered, sold, transferred, or encumbered. Shares cannot be registered, sold, transferred or encumbered until any loan in relation to the Shares has been repaid or otherwise discharged under the Plan.
- (f) **Unfulfilled Vesting Condition:** Where a vesting condition in relation to Shares is not satisfied by the due date, or becomes incapable of satisfaction in the opinion of the Board, the Company must, unless the vesting condition is waived by the Board, either:
  - (i) buy back and cancel the relevant Shares within 12 months of the date the vesting condition was not satisfied (or became incapable of satisfaction) under Part 2J.1 of the Corporations Act at a price equal to the cash consideration paid by the participant for the Shares (with any Loan not being treated as cash consideration but any Loan Amount repayments by the participant being treated as cash consideration); or

- (ii) arrange to sell the Shares as soon as reasonably practicable either on the ASX or to an investor who falls within an exemption under section 708 of the Corporations Act provided that the sale must be at a price that is no less than 80% of the volume weighted average price at which Shares were traded on the ASX on the 10 trading days before the sale date and apply the sale proceeds (Sale Proceeds) in the following priority:
  - (A) first, to pay the Company any outstanding Loan Amount (if any) in relation to the Shares and the Company's reasonable costs in selling the Shares;
  - (B) second, to the extent the Sale Proceeds are sufficient, to repay the Participant any cash consideration paid by the Participant or Loan Amount repayments (including any cash dividends applied to the Loan Amount) made by or on behalf of the Participant; and
  - (C) lastly, any remainder to the Company to cover its costs of managing the Plan.
- (g) **Loan:** An Employee who is invited to subscribe for Shares may also be invited to apply for a loan up to the amount payable in respect of the Shares accepted by the Employee (**Loan**), on terms as determined by the Board.
- (h) **Power of Attorney:** The Employee irrevocably appoints each of the Company and each director of the Company severally as his or her attorney to do all things necessary to give effect to the sale of the Employee's Shares in accordance with the Plan.
- (i) **Plan limit:** The Company must take reasonable steps to ensure that the number of Shares offered by the Company under the Plan must not exceed 10% of the total number of issued Shares in order to comply with the Corporations Act and relevant ASIC Class Orders.
- (j) **Quotation on ASX:** The Company will apply for each Plan Share to be admitted to trading on ASX upon issue of the Plan Share. Quotation will be subject to the ASX Listing Rules and any holding lock applying to the Shares.
- (k) **Rights attaching to Shares**: Each Plan Share shall be issued on the same terms and conditions as the Company's issued Shares (other than in respect of vesting conditions imposed by the Plan) and it will rank equally with all other issued Shares from the issue date except for entitlements which have a record date before the issue date.





→ 000001 000 AVH MR SAM SAMPLE FLAT 123 123 SAMPLE STREET THE SAMPLE HILL SAMPLE ESTATE SAMPLEVILLE VIC 3030

## Lodge your vote:



www.investorvote.com.au



## By Mail:

Computershare Investor Services Pty Limited GPO Box 242 Melbourne Victoria 3001 Australia

Alternatively you can fax your form to (within Australia) 1800 783 447 (outside Australia) +61 3 9473 2555

For Intermediary Online subscribers only (custodians) www.intermediaryonline.com

## For all enquiries call:

(within Australia) 1300 850 505 (outside Australia) +61 3 9415 4000

## **Proxy Form**



#### Vote online

- •Go to www.investorvote.com.au or scan the QR Code with your mobile device.
- Follow the instructions on the secure website to vote.

## Your access information that you will need to vote:

Control Number: 999999

SRN/HIN: 19999999999 PIN: 99999

PLEASE NOTE: For security reasons it is important that you keep your SRN/HIN confidential.



## 🌣 For your vote to be effective it must be received by 11:00am (EST) Saturday, 22 August 2015

## How to Vote on Items of Business

All your securities will be voted in accordance with your directions.

## **Appointment of Proxy**

Voting 100% of your holding: Direct your proxy how to vote by marking one of the boxes opposite each item of business. If you do not mark a box your proxy may vote or abstain as they choose (to the extent permitted by law). If you mark more than one box on an item your vote will be invalid on that item.

Voting a portion of your holding: Indicate a portion of your voting rights by inserting the percentage or number of securities you wish to vote in the For, Against or Abstain box or boxes. The sum of the votes cast must not exceed your voting entitlement or 100%

Appointing a second proxy: You are entitled to appoint up to two proxies to attend the meeting and vote on a poll. If you appoint two proxies you must specify the percentage of votes or number of securities for each proxy, otherwise each proxy may exercise half of the votes. When appointing a second proxy write both names and the percentage of votes or number of securities for each in Step 1 overleaf.

A proxy need not be a securityholder of the Company.

## Signing Instructions for Postal Forms

Individual: Where the holding is in one name, the securityholder must sign.

Joint Holding: Where the holding is in more than one name, all of the securityholders should sign.

Power of Attorney: If you have not already lodged the Power of Attorney with the registry, please attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: Where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the Corporations Act 2001) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please sign in the appropriate place to indicate the office held. Delete titles as applicable.

#### Attending the Meeting

Bring this form to assist registration. If a representative of a corporate securityholder or proxy is to attend the meeting you will need to provide the appropriate "Certificate of Appointment of Corporate Representative" prior to admission. A form of the certificate may be obtained from Computershare or online at www.investorcentre.com under the help tab, "Printable Forms".

Comments & Questions: If you have any comments or questions for the company, please write them on a separate sheet of paper and return with this form.

GO ONLINE TO VOTE, or turn over to complete the form

MR SAM SAMPLE FLAT 123
123 SAMPLE STREET
THE SAMPLE HILL
SAMPLE ESTATE
SAMPLEVILLE VIC 3030

Change of address. If incorrect,
mark this box and make the
correction in the space to the left.
Securityholders sponsored by a
broker (reference number
commences with 'X') should advise
your broker of any changes



I 999999999

IND

Proxy Form	Please	mark X	to indicate your directions			
Appoint a Proxy to Vote on Your Behalf						
I/We being a member/s of Avita Medica	al Limited hereby appoint		AA.			
the Chairman of the Meeting			PLEASE NOTE: Leave this box blank if you have selected the Chairman of the Meeting. Do not insert your own name(s).			
to act generally at the Meeting on my/our behad to the extent permitted by law, as the proxy se	or failing the individual or body corporate named, or if no individual or body corporate is named, the Chairman of the Meeting, as my/our proxy to act generally at the Meeting on my/our behalf and to vote in accordance with the following directions (or if no directions have been given, and to the extent permitted by law, as the proxy sees fit) at the General Meeting of Avita Medical Limited to be held at Level 12, 15 William Street, Melbourne, Victoria on Monday, 24 August 2015 at 11:00am (EST) and at any adjournment or postponement of that Meeting.					
Chairman authorised to exercise undirected proxies on remuneration related resolution: Where I/we have appointed the Chairman of the Meeting as my/our proxy (or the Chairman becomes my/our proxy by default), I/we expressly authorise the Chairman to exercise my/our proxy on Resolution 4 (except where I/we have indicated a different voting intention below) even though Resolution 4 is connected directly or indirectly with the remuneration of a member of key management personnel, which includes the Chairman.						
Important Note: If the Chairman of the Meeting is (or becomes) your proxy you can direct the Chairman to vote for or against or abstain from voting on Resolution 4 by marking the appropriate box in step 2 below.						
STEP 2 Items of Business	PLEASE NOTE: If you mark the Abstain box for an ibehalf on a show of hands or a poll and your votes w					
Resolution 1 Ratification of Prior Issue of Shar	res – ASX Listing Rule 7.1					
Resolution 2 Ratification of Prior Issue of Shar	res – ASX Listing Rule 7.1A					
Resolution 3 Approval to Issue Shares Under	Placement					
Resolution 4 Adoption of Employee Share Pla	n Incentive Plan					
The Chairman of the Meeting intends to vote undirection change his/her voting intention on any resolution, in	eted proxies in favour of each item of business. In exce which case an ASX announcement will be made.	ptional circumst	ances, the Chairman of the Meeting may			
SIGN Signature of Securityholder(s) This section must be completed.						
Individual or Securityholder 1	Securityholder 2	Securityhol	der 3			
Sole Director and Sole Company Secretary	Director	Director/Co	mpany Secretary			

Date

Contact

Name

Contact

Daytime

Telephone